H
Helen M. Colhoun
Researcher at University of Edinburgh
Publications - 320
Citations - 26513
Helen M. Colhoun is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 71, co-authored 303 publications receiving 22353 citations. Previous affiliations of Helen M. Colhoun include University College London & NHS Fife.
Papers
More filters
Journal ArticleDOI
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Helen M. Colhoun,D. John Betteridge,Paul N. Durrington,Graham A. Hitman,H. Andrew W. Neil,Shona Livingstone,Margaret J Thomason,Michael I. Mackness,Valentine Charlton-Menys,John H. Fuller +9 more
TL;DR: Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol.
Journal ArticleDOI
Problems of reporting genetic associations with complex outcomes.
TL;DR: It is suggested that the most important factors underlying inability to replicate these associations are publication bias, failure to attribute results to chance, and inadequate sample sizes, problems that are all rectifiable.
Journal ArticleDOI
Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials
Jordan Fulcher,Rachel O'Connell,Merryn Voysey,Jonathan Emberson,L Blackwell,Borislava Mihaylova,John Simes,Rory Collins,Adrienne Kirby,Helen M. Colhoun,Eugene Braunwald,J La Rosa,Terje R. Pedersen,Andrew Tonkin,Barry R. Davis,Peter Sleight,MariaGrazia Franzosi,Colin Baigent,Anthony C Keech +18 more
TL;DR: In men and women at an equivalent risk of cardiovascular disease, statin therapy is of similar effectiveness for the prevention of major vascular events.
Journal ArticleDOI
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker,Jean G. MacFadyen,Tom Thuren,Brendan M. Everett,Peter Libby,R J Glynn,Paul Ridker,Alberto J. Lorenzatti,Henry Krum,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antonio Helfenstein Fonseca,Jose C. Nicolau,Nina Gotcheva,Jacques Genest,Huo Yong,Miguel Urina-Triana,Davor Miličić,Renata Cifkova,Riina Vettus,Wolfgang Koenig,Stephan D Anker,Athanasios J. Manolis,Fernando Wyss,Tamás Forster,Axel Sigurdsson,Prem Pais,Alessandro Fucili,Hisao Ogawa,Hiroaki Shimokawa,Irina Veze,Birute Petrauskiene,Leon Salvador,John J.P. Kastelein,Jan H. Cornel,Tor Ole Klemsdal,Félix Medina,Andrzej Budaj,Luminita Vida-Simiti,Zhanna Kobalava,Petar Otasevic,Daniel Pella,Mitja Lainscak,Ki-Bae Seung,Patrick J. Commerford,Mikael Dellborg,Marc Y. Donath,Juey-Jen Hwang,Hakan Kultursay,Marcus Flather,Christie M. Ballantyne,Seth Bilazarian,William Chang,Cara East,Brendan Everett,Les Forgosh,Robert J. Glynn,Barry Harris,Monica Ligueros,Erin A. Bohula,Bindu Charmarthi,Susan Cheng,Sherry Chou,Jacqueline Danik,Graham McMahon,Bradley Maron,MingMing Ning,Benjamin Olenchock,Reena Pande,Todd Perlstein,Aruna D. Pradhan,Natalia Rost,Aneesh Singhal,Viviany Taqueti,Nancy Wei,Howard A. Burris,Angela Cioffi,Anne Marie Dalseg,Nilanjan Ghosh,Julie R. Gralow,Tina Mayer,Hope S. Rugo,Vance G. Fowler,Ajit P. Limaye,Sara Cosgrove,Donald Levine,Renato D. Lopes,John D. Scott,Robert Hilkert,Georgia Tamesby,Carolyn Mickel,Brian Manning,Julian Woelcke,Monique Tan,Sheryl Manfreda,Tom Ponce,Jane Kam,Ravinder Saini,Kehur Banker,Thomas Salko,Panjat Nandy,Ronda Tawfik,Greg O'Neil,Shobha Manne,Pravin Jirvankar,Shankar Lal,Deepak Nema,Jaison Jose,Rory Collins,Kent Bailey,Roger S. Blumenthal,Helen M. Colhoun,Bernard J. Gersh +113 more
TL;DR: The hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality.
Journal ArticleDOI
Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis
S. Matthijs Boekholdt,Benoit J. Arsenault,Samia Mora,Terje R. Pedersen,John C. LaRosa,Paul J. Nestel,R. John Simes,Paul N. Durrington,Graham A. Hitman,K. M. A. Welch,David A. DeMicco,Aeilko H. Zwinderman,Michael Clearfield,John R. Downs,Andrew Tonkin,Helen M. Colhoun,Antonio M. Gotto,Paul M. Ridker,John J.P. Kastelein +18 more
TL;DR: Among statin-treated patients, on-treatment levels of LDL-C, non-HDL-C and apoB were each associated with risk of future major cardiovascular events, but the strength of this association was greater for non- HDL-C than for LDL-B and apolipoproteins.